Envue Medical Inc. has amended and restated its 2024 Long Term Incentive Plan. The updated plan expands the definition of awards to include restricted stock units and other types of awards to accommodate Israeli tax requirements. The amendment also incorporates updates reflecting the company’s recent name change from NanoVibronix, Inc. to Envue Medical, Inc.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envue Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-029482), on December 30, 2025, and is solely responsible for the information contained therein.